AI is transforming industries, and biopharma is no exception. AI will help make better drugs, hopefully more efficiently, and will aid in bringing those medicines to patients with expedience.

But here’s my prediction: AI will drive a wave of drug abundance and exacerbate the industry’s aggregate R&D productivity challenges over the next 3-5 years, rather than improve those metrics.

Great new technology waves often make things worse before they make them better.  In 2001, at the peak of the Genomics Bubble, Lehman Brothers and McKinsey put out a report called “The Fruits of Genomics: Drug Pipelines Face Indigestion Until the New Biology Ripens” – which hypothesized that with the increased understanding of the human genome sequence, industry labs would be flooded with first-in-class unprecedented biologic targets – and new era of Target Abundance – all of which had little validation, which would lead to a spike in failure rates, elevated costs, and longer timelines. All very much counter to the “promise” that genomics would improve those things.  The industry’s R&D Productivity declines for much of this century largely validate the Target Abundance thesis of that report. But no one would doubt that the Human Genome Project was of huge value to medicine today.